1.Biflorin Ameliorates Memory Impairments Induced by Cholinergic Blockade in Mice.
Se Jin JEON ; Boseong KIM ; Byeol RYU ; Eunji KIM ; Sunhee LEE ; Dae Sik JANG ; Jong Hoon RYU
Biomolecules & Therapeutics 2017;25(3):249-258
To examine the effect of biflorin, a component of Syzygium aromaticum, on memory deficit, we introduced a scopolamine-induced cognitive deficit mouse model. A single administration of biflorin increased latency time in the passive avoidance task, ameliorated alternation behavior in the Y-maze, and increased exploration time in the Morris water maze task, indicating the improvement of cognitive behaviors against cholinergic dysfunction. The biflorin-induced reverse of latency in the scopolamine-treated group was attenuated by MK-801, an NMDA receptor antagonist. Biflorin also enhanced cognitive function in a naïve mouse model. To understand the mechanism of biflorin for memory amelioration, we performed Western blot. Biflorin increased the activation of protein kinase C-ζ and its downstream signaling molecules in the hippocampus. These results suggest that biflorin ameliorates drug-induced memory impairment by modulation of protein kinase C-ζ signaling in mice, implying that biflorin could function as a possible therapeutic agent for the treatment of cognitive problems.
Animals
;
Blotting, Western
;
Cognition
;
Cognition Disorders
;
Dizocilpine Maleate
;
Hippocampus
;
Memory Disorders
;
Memory*
;
Mice*
;
N-Methylaspartate
;
Protein Kinases
;
Syzygium
;
Water
2.Amyotrophic Lateral Sclerosis Associated With CADASIL.
Jookyung LEE ; Hyun Jung JANG ; Boseong KWON ; Young Min LIM ; Kwang Kuk KIM
Journal of the Korean Neurological Association 2013;31(3):209-210
No abstract available.
Amyotrophic Lateral Sclerosis
;
CADASIL
3.Amyotrophic Lateral Sclerosis Associated With CADASIL.
Jookyung LEE ; Hyun Jung JANG ; Boseong KWON ; Young Min LIM ; Kwang Kuk KIM
Journal of the Korean Neurological Association 2013;31(3):209-210
No abstract available.
Amyotrophic Lateral Sclerosis
;
CADASIL
4.Validation of Korean Pediatric Resuscitation Tape
Boseong KIM ; Hye Young JANG ; Hyun NOH ; Suyeon PARK ; Youngjoo LEE ; Young Shin CHO ; Joonbum PARK ; Heajin CHUNG ; Sang-Il KIM ; Beom Sok SEO ; Young Wha SOHN
Journal of the Korean Society of Emergency Medicine 2022;33(5):429-435
Objective:
Various tools using the length-based method for weight estimation and decisions regarding equipment size have been used in pediatric resuscitation globally. The Korean Pediatric Resuscitation Tape (KPRT) is one such tool that has been developed recently. This study was performed to validate the use of KPRT in Korean children.
Methods:
Data on the measured weights and the endotracheal tube (ETT) sizes used for children aged 12 years or less, who received general anesthesia, were collected by reviewing medical records from June 2018 to October 2020 at two hospitals in the urban areas of Korea. We compared the weight and ETT size estimated by the KPRT to the actually measured weight and ETT size used for the study population. We also calculated the weight and ETT size using an age-based formula and compared these values to the actual values of the patients. We then analyzed the agreement between these estimated values and the actual values of the children.
Results:
A total of 1,237 children were included in this study. The intra-class correlation coefficient of agreement between the actual weight and estimated weight by the KPRT was 0.94 compared to 0.93 when estimated by the age-based formula. The weighted kappa coefficient of the agreement between the ETT size actually used, and the size estimated by the KPRT was 0.61 compared to 0.74 when estimated by the age-based formula. The estimated ETT sizes using the KPRT were smaller than the actual size used in children under three years old, whereas it was larger for children aged eight years or more.
Conclusion
Our study showed that the KPRT was a dependable tool for estimating the weight and ETT size of Korean children. Future studies would be needed to augment the reliability of the KPRT in pediatric resuscitation.
5.Endovascular Treatment of Arterial Steno-Occlusive Lesions in Symptomatic Moyamoya Disease
Jae-Chan RYU ; Yun Hyeok CHOI ; Mi Hyeon KIM ; Eun Ji MOON ; Youngjin KIM ; Boseong KWON ; Yunsun SONG ; Deok Hee LEE
Neurointervention 2022;17(3):161-167
The efficacy and safety of endovascular treatment (EVT) for moyamoya disease (MMD) have rarely been investigated. The objective of this study was to summarize the clinical outcomes of EVT for MMD and determine the potential role of EVT in treating symptomatic steno-occlusive lesions in MMD. Reports from January 2000 to December 2021 describing EVT in MMD were collected through a literature search. The search terms included “moyamoya”, “stent”, “angioplasty”, and “endovascular”. Data regarding baseline demographics, previous medical history, treated vessel, periprocedural complications, and angiographical recurrence were retrieved. This review included 10 studies with details of 19 patients undergoing a total of 31 EVT procedures. Twenty-one EVTs were performed as initial treatments for MMD, and 10 were performed as additional treatments for angiographical recurrence. The mean follow-up period of the initial EVTs was 9.0±11.9 months, with angiographical recurrence in 11 (68.8%) cases. The mean follow-up period of additional EVTs was 4.3±3.9 months, and seven (70.0%) EVTs showed restenosis of the re-treated vessel. Across all initial and additional EVTs, there were no differences in characteristics between the recurrence and non-recurrence groups. Overall, two periprocedural complications (9.5%) occurred, one vessel rupture and one massive intracerebral hemorrhage with subarachnoid hemorrhage. EVT plays a limited role in the management of symptomatic intracranial arterial steno-occlusive lesions of MMD. Recent advances in understanding the pathomechanism of MMD may urge neuro-interventionists to find a new endovascular approach with better balloon angioplasty or stenting mechanisms.
6.Effect of Intravenous Thrombolysis Prior to Mechanical Thrombectomy According to the Location of M1 Occlusion
Jae-Chan RYU ; Boseong KWON ; Yunsun SONG ; Deok Hee LEE ; Jun Young CHANG ; Dong-Wha KANG ; Sun U. KWON ; Jong S. KIM ; Bum Joon KIM
Journal of Stroke 2024;26(1):75-86
Background:
and Purpose The additive effects of intravenous thrombolysis (IVT) before mechanical thrombectomy (MT) remain unclear. We aimed to investigate the efficacy and safety of IVT prior to MT depending on the location of M1 occlusion.
Methods:
We reviewed the cases of patients who underwent MT for emergent large-vessel occlusion of the M1 segment. Baseline characteristics as well as clinical and periprocedural variables were compared according to the location of M1 occlusion (i.e., proximal and distal M1 occlusion). The main outcome was the achievement of functional independence (modified Rankin Scale score, 0–2) at 3 months after stroke. The main outcomes were compared between the proximal and distal groups based on the use of IVT before MT.
Results:
Among 271 patients (proximal occlusion, 44.6%; distal occlusion, 55.4%), 33.9% (41/121) with proximal occlusion and 24.7% (37/150) with distal occlusion underwent IVT prior to MT. Largeartery atherosclerosis was more common in patients with proximal M1 occlusion; cardioembolism was more common in those with distal M1 occlusion. In patients with proximal M1 occlusion, there was no association between IVT before MT and functional independence. In contrast, there was a significant association between the use of IVT prior to MT (odds ratio=5.30, 95% confidence interval=1.56–18.05, P=0.007) and functional independence in patients with distal M1 occlusion.
Conclusion
IVT before MT was associated with improved functional outcomes in patients with M1 occlusion, especially in those with distal M1 occlusion but not in those with proximal M1 occlusion.
7.Spinosin, a C-Glucosylflavone, from Zizyphus jujuba var. spinosa Ameliorates Abeta1-42 Oligomer-Induced Memory Impairment in Mice.
Sang Yoon KO ; Hyung Eun LEE ; Se Jin PARK ; Se Jin JEON ; Boseong KIM ; Qingtao GAO ; Dae Sik JANG ; Jong Hoon RYU
Biomolecules & Therapeutics 2015;23(2):156-164
Alzheimer's disease (AD) is a neurodegenerative disorder associated with progressive memory loss and neuronal cell death. Although numerous previous studies have been focused on disease progression or reverse pathological symptoms, therapeutic strategies for AD are limited. Alternatively, the identification of traditional herbal medicines or their active compounds has received much attention. The aims of the present study were to characterize the ameliorating effects of spinosin, a C-glucosylflavone isolated from Zizyphus jujuba var. spinosa, on memory impairment or the pathological changes induced through amyloid-beta1-42 oligomer (AbetaO) in mice. Memory impairment was induced by intracerebroventricular injection of AbetaO (50 muM) and spinosin (5, 10, and 20 mg/kg) was administered for 7 days. In the behavioral tasks, the subchronic administration of spinosin (20 mg/kg, p.o.) significantly ameliorated AbetaO-induced cognitive impairment in the passive avoidance task or the Y-maze task. To identify the effects of spinosin on the pathological changes induced through AbetaO, immunohistochemistry and Western blot analyses were performed. Spinosin treatment also reduced the number of activated microglia and astrocytes observed after AbetaO injection. In addition, spinosin rescued the AbetaO-induced decrease in choline acetyltransferase expression levels. These results suggest that spinosin ameliorated memory impairment induced through AbetaO, and these effects were regulated, in part, through neuroprotective activity via the anti-inflammatory effects of spinosin. Therefore, spinosin might be a useful agent against the amyloid b protein-induced cognitive dysfunction observed in AD patients.
Alzheimer Disease
;
Amyloid
;
Animals
;
Astrocytes
;
Blotting, Western
;
Cell Death
;
Choline O-Acetyltransferase
;
Disease Progression
;
Humans
;
Immunohistochemistry
;
Memory Disorders
;
Memory*
;
Mice*
;
Microglia
;
Neurodegenerative Diseases
;
Neurons
;
Ziziphus*
9.In Vitro Head-to-Head Comparison of Flow Reduction between Fibered and Non-Fibered Pushable Coils
Jong-Tae YOON ; Boseong KWON ; Joon Ho CHOI ; Sun Moon HWANG ; Mihyeon KIM ; Sungbin HWANG ; Yunsun SONG ; Deok Hee LEE
Neurointervention 2024;19(1):31-38
Purpose:
To compare the embolization effects of a non-fibered pushable coil with a conventional fibered pushable coil in an in vitro bench-top experiment.
Materials and Methods:
A simplified vascular phantom with 4 channels (1 for the non-fibered coil, 1 for the fibered coil, and 2 for continuous circuit flow) was used. A single coil of the longest length was inserted to evaluate the effect of single-coil embolization, and 3 consecutive coils were inserted to assess the effect of multiple-coil embolization. Post-embolization angiography was performed to obtain flow variables (time to peak [TTP], relative peak intensity [rPI], and angiographic flow reduction score [AFRS]) from time density curves. The packing densities of the two coil types were calculated, and the AFRS of each channel was determined by dividing the TTP by the rPI.
Results:
When inserting a single coil, the conventional fibered coil demonstrated better flow reduction, as indicated by a higher AFRS (25.6 vs. 17.4, P=0.034). However, the non-fibered coil exhibited a significantly higher packing density (12.9 vs. 2.4, P=0.001). Similar trends were observed with multiple coils.
Conclusion
The conventional fibered pushable coil showed better flow reduction efficiency, while the non-fibered pushable coil had a higher packing density, likely due to the flexibility of the coil loops. A better understanding of the distinct characteristics of different pushable coils can enhance the outcomes of various vascular embolization.
10.Long-Term Changes in Post-Stroke Depression, Emotional Incontinence, and Anger
Boseong KWON ; Eun-Jae LEE ; Seongho PARK ; Ji Sung LEE ; Min Hwan LEE ; Daeun JEONG ; Dongwhane LEE ; Hyuk Sung KWON ; Dae-Il CHANG ; Jong-Ho PARK ; Jae-Kwan CHA ; Ji Hoe HEO ; Sung-Il SOHN ; Dong-Eog KIM ; Smi CHOI-KWON ; Jong S. KIM
Journal of Stroke 2021;23(2):263-272
Background:
and Purpose Long-term changes in post-stroke depression (PSD), post-stroke emotional incontinence (PSEI), and post-stroke anger (PSA) have rarely been studied.
Methods:
This is a sub-study of EMOTION, a randomized, placebo-controlled trial, that examined the efficacy of escitalopram on PSD, PSEI, and PSA in patients with stroke. We interviewed patients at the long-term period (LTP) using predefined questionnaires: Montgomery-Åsberg depression rating scale (MADRS) for PSD, modified Kim’s criteria for PSEI, and Spielberger trait anger scale for PSA. Additionally, the ENRICHD Social Support Instrument (ESSI) for the social support state and the modified Rankin Scale (mRS) were measured. We investigated the changes in and factors behind PSD, PSEI, and PSA at LTP.
Results:
A total of 222 patients were included, and the median follow-up duration was 59.5 months (interquartile range, 50 to 70). Compared to the data at 6 months post-stroke, the prevalence of PSEI (11.7% at 6 months, 6.3% at LTP; P=0.05) and mean anger score (21.62, 16.24; P<0.01) decreased, while the prevalence of PSD (35.6%, 44.6%; P=0.03) and mean MADRS (6.16, 8.67; P<0.01) increased at LTP. ESSI was associated with PSD and PSA, but not with PSEI. The effect of the baseline National Institutes of Health Stroke Scale score on PSD decreased over time. The effect of low social support on PSD was greater than that of mRS at LTP.
Conclusions
The prevalence and degree of PSD significantly increased, while those of PSEI and PSA decreased at LTP. PSD in this stage appeared to be more closely associated with a lack of social support than patients' physical disabilities.